Morgan Stanley
AAPG

Morgan Stanley’s Ascentage Pharma AAPG Stock Holding History

Morgan Stanley’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9K Buy
498
+345
+225% +$8.49K ﹤0.01% 6897
2025
Q4 		$4.01K Sell
153
-50
-25% -$1.64K ﹤0.01% 7105
2025
Q3 		$7.92K Sell
203
-753
-79% -$30.5K ﹤0.01% 6964
2025
Q2 		$37.6K Buy
+956
New +$25.2K ﹤0.01% 6448

Other funds holding AAPG

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Morgan Stanley's AAPG Position: Q1 2026 in Review

Morgan Stanley increased its Ascentage Pharma (AAPG) stake by 225% in Q1 2026, buying an estimated $8.49K and bringing the position to 498 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6897.

Morgan Stanley first reported a position in AAPG in Q2 2025 and has held it in 4 quarters since. The position peaked at $37.6K in Q2 2025. 7 funds tracked by Wall St. Rank hold AAPG as of Q1 2026.

  • Morgan Stanley held 498 shares of Ascentage Pharma worth $11.9K as of Q1 2026.
  • Morgan Stanley bought 345 Ascentage Pharma shares in Q1 2026, an estimated $8.49K.
  • Ascentage Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6897 holding.
  • Morgan Stanley first reported a position in Ascentage Pharma in Q2 2025 and has held it in 4 quarters since.
  • Morgan Stanley's Ascentage Pharma position peaked at $37.6K in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Ascentage Pharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.